Solve | The People of SKC
SKC is an open-source organization built on the spirit of collaboration and partnership. The work of SKC wouldn’t be possible without all of the solution-driven people behind it, from our board members to our staff. Learn more about everyone involved by clicking through the following member groups.
Board of Directors
SKC's board brings together the knowledge and expertise of a diverse range of people -- from scientific advisors to parents of children who experienced cancer. In the spirit of collaboration, the board guides the progressive direction of SKC by focusing strategies and establishing priorities on the goal of making survivorship possible.
John London MBA
Co-founder, Chairman of the Board
The inspiration for John London in co-founding Solving Kids' Cancer belongs solely to his daughter, Penelope, who once told him "I want no one to feel yucky Daddy". The mission of both his life and that of Catherine's is to make sure that no other children and families suffer the loss his family has had to endure with the passing of Penelope. As Chairman of the Board of Directors, John has primary responsibilities with SKC that include leadership and overall management of organizational governance, compliance, donor cultivation, and fundraising. John also serves as a strategic advisor in all areas of therapeutic development. John also co-founded and currently serves as general partner for SuttonBrook Capital Management, an investment fund based in New York City. He has an MBA from The Wharton School of Business, University of Pennsylvania and a Bachelor of Arts from Brown University.
Scott Kennedy MBA
Co-founder, Executive Director
Scott co-founded SKC in 2007 as a tribute to his son, Hazen Kennedy, who was diagnosed with neuroblastoma at age 3. Hazen was Scott's inspiration for creating Solving Kids' Cancer in part because Hazen wanted to become a scientist when he grew up in order to help people by creating new medicines. As Executive Director, Scott Kennedy is involved in all aspects of SKC, from managing operational staff and fundraising to policy development and fiscal management. He is integrally involved in the identification, funding, and management of the organization's scientific programs. Before co-founding SKC, Scott worked in marketing at CDW in Chicago and Pfizer in New York City. He also founded a New York City theatre and sightseeing business, Manfreakinhattan. Scott has a Bachelor of Science in Chemistry and Psychology from Indiana University and a MBA from the Asian Institute of Management.
Managing Director, The Invus Group
Catherine London JD
Wayne Robinson CPA, MT
Managing Director, Barclays
Channing Stave PhD
Senior Director, Market Insights at Medco Health Solutions
Therapeutic Development Initiative (TDI) Scientific Advisory Board
The TDI Scientific Advisory Board assembles a diverse wealth of knowledge and experience of scientists who represent multiple disciplines in cancer. SKC's TDI board is comprised of both leading pediatric oncologists and researchers, as well as experts from other key disciplines including immunology, systems biology, adult oncology, and clinical trial design. Together they ensure continuous innovation and creative thinking in the development of therapeutic agents for pediatric cancer.
Hearn Jay Cho MD, PhD
Assistant Professor of Medicine, Hematology and Medical Oncology, Mount Sinai Hospital
Dr. Cho is an Assistant Professor of Medicine at Tisch Cancer Institute, Mount Sinai Hospital. His laboratory is investigating the tumor immunology and molecular biology of multiple myeloma, a cancer of the blood and bone marrow. Dr. Cho is the chairperson of the Multiple Myeloma Working Group sponsored by the Cancer Research Institute and the Ludwig Institute for Cancer Research. This international collaborative of Ludwig-affiliated laboratories is dedicated to developing clinical trials of novel immunologic therapies for this disease. Dr. Cho received his undergraduate degree in Molecular Biology from Princeton University and is a graduate of the Tri-Institutional MD-PhD Program of Cornell University Medical College with a doctoral degree in Immunology. Dr. Cho was a resident in the Clinical Investigator Track in the Department of Internal Medicine at the University of California, San Diego, where he also did a post-doctoral research fellowship in Immunology. Dr. Cho completed his clinical fellowship in Hematology and Medical Oncology at The New York-Presbyterian Hospital/ Cornell Medical Center and was a visiting research fellow at the Rockefeller University. Prior to joining the faculty at NYU, Dr. Cho was an Assistant Professor of Medicine at Weill Medical College of Cornell University.
Kenneth Cohen MD, MBA
Director Pediatric Neuro-oncology, Johns Hopkins University
Dr. Cohen serves on SKC’s scientific advisory board, where he helps define the organization’s scientific approach and research priorities. Additionally, as an Executive Officer of the TDI advisory board he is actively involved in the daily operations of the TDI including the grants solicitation and review process. He is currently the Director of Pediatric Neuro-Oncology and the Clinical Director in the Division of Pediatric Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital. He joined the faculty at Johns Hopkins in 1994, after completing his Pediatric Hematology/Oncology Fellowship. The Pediatric Neuro-Oncology program’s major focus is the development and testing of novel therapeutics for children with brain tumors. Research is also coordinated with the neuropsychology group at the Kennedy-Krieger Institute. He serves as the co-chair of the High-Grade Glioma committee for the Children’s Oncology Group where his focus is the development of therapeutics for the treatment of infiltrating gliomas. Dr. Cohen is a scientific advisor for the Childhood Brain Tumor Foundation. He received his undergraduate degree at Brown University and his MD from the State University of New York Upstate Medical Center in 1987. He completed his residency and Chief Residency in Pediatrics at the University Of Colorado School of Medicine in 1991.
David Kaplan PhD
Neuroblastoma Basic Researcher Senior Scientist, Cell Biology Program, Hospital for Sick Children Professor, Department of Molecular Genetics University of Toronto
Dr. Kaplan is a Senior Scientist and Co-Head of the Comprehensive Cancer Centre at the Hospital for Sick Children Research Institute, a Professor at the University of Toronto, and holder of the Canada Research Chair in Cancer and Neuroscience. He has made several discoveries in the signal transduction field. Dr. Kaplan obtained his BA from Clark University in Massachusetts, his PhD from Harvard University with Dr. Thomas Roberts in 1987, and completed his postdoctoral training with Dr. Harold Varmus at the University of California, San Francisco in 1990. At his laboratory in Toronto he is the Head of the Cancer Research Program at the Hospital for Sick Children. He is also a member of the Canadian Stem Cell Network, where he leads a high throughput screening effort to identify new drugs to treat cancer using cancer stem cells, with an emphasis on neuroblastoma.
Mark Kieran MD, PhD
Pediatric Neuro-oncologist, Dana-Farber Cancer Institute
Dr. Kieran received his PhD in 1983 from the University of Alberta, Edmonton, Canada, and his MD in 1986 from the University of Calgary. He completed postgraduate training in molecular biology at the Pasteur Institute in Paris. After a pediatric residency in Montreal, he received postdoctoral education at Children's Hospital Boston. In 1999, he became Director of Pediatric Neuro-Oncology at Dana-Farber Cancer Institute. He also works on angiogenesis in the laboratory of the late Dr. Judah Folkman, and in 2002 Dr. Kieran received the Nick Palmer Award and Lecture, London, UK. Dr. Kieran is most known for his research efforts. His laboratory selects promising agents and evaluates them in human tumors which have been orthotopically implanted into mice. This process quickly moves potential therapies into the clinic. At present, more than five such projects are ongoing in conjunction with different groups at DFCI, BWH, BIDMC, and CHB.
David Loeb MD, PhD
Director of the Musculoskeletal Tumor Program, John Hopkins University
Dr David Loeb is a member of the SKC TDI Scientific Advisory Board and a prominent physician-scientist in the field of pediatric sarcomas. He has two primary research interests: the role of WT1 gene in the growth of solid tumors in childhood, and the development of targeted therapies aimed at sarcoma stem cells. Dr Loeb is Associate Professor of Oncology and Associate Professor of Pediatrics at John Hopkins University. He received his BA in Biology from Johns Hopkins University in 1987, his PhD in 1993 and his MD in 1994, both from Columbia University, and completed his internship, residency, and fellowship at John Hopkins. In fact, three of his publications in graduate school were co-authored with fellow SAB member Dr David Kaplan. Dr Loeb authors a popular blog on his experience as a pediatric oncologist "Dr David's Blog" http://doctordavidsblog.blogspot.com/, written for anyone interested in pediatric oncology, cancer research, cancer treatments, and breaking medical news.
Chrystal Louis MD, MPH
Assistant Professor, Department of Pediatrics Section of Hematology-Oncology Baylor College of Medicine
Dr. Louis is a member of the translational research laboratory in the Center for Cell and Gene Therapy. In association with Dr. Stephen Gottschalk and Dr. Helen Heslop, she has been working on methods to improve immunotherapy options for patients with solid tumors. At this time, she has focused her research on therapeutic strategies for patients with either nasopharyngeal carcinoma (NPC) or neuroblastoma. Most cases of advanced-stage NPC are associated with Epstein Barr virus (EBV), and our center previously determined that administration of adoptively transferred EBV-specific cytotoxic T lymphocytes (EBV-CTL) was safe and produced anti-tumor effects in 50% of patients. Therefore, Dr. Chrystal Louis' current research efforts have focused on improving the specificity of the CTL product for NPC tumors and identifying additional, non-EBV associated tumor markers that can also be used as immunotherapy targets. For patients with high-risk neuroblastoma, prior studies have shown clinical responses after active immunization; however, responses were limited by the poorly immunogenic nature of neuroblastoma tumor-cell vaccines. Dr. Chrystal Louis and colleagues are now investigating the safety, immune response, and anti-tumor activity of more potent, genetically modified neuroblastoma tumor cell vaccines after high-dose chemotherapy and stem cell rescue. Additionally, the group is continuing their study using adoptively transferred T cells modified to express receptors for GD2 in patients with a history of high-risk neuroblastoma.
Tobey J. MacDonald MD
Director, Pediatric Neuro-Oncology Program Aflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta Associate Professor of Pediatrics, Emory University School of Medicine
Dr. MacDonald received his MD from Cornell University in 1991 and completed his pediatric internship, residency and post-graduate fellowship training in hematology-oncology and neuro-oncology all at the Children's Hospital Los Angeles from 1992-1998. In 1998, he became the Clinical Director of Neuro-Oncology in the Division of Hematology-Oncology at Children's National Medical Center in Washington, DC, where he served until 2009. He then joined the faculty as an Associate Professor in the Department of Pediatrics of Emory University School of Medicine and Director of the Pediatric Neuro-Oncology Program of the Aflac Cancer Center of Children's Healthcare of Atlanta in 2009. Dr. MacDonald has built an international reputation as a leader in the field of pediatric neuro-oncology for clinical, basic and translational research. Dr. MacDonald's research focuses primarily on identifying the molecular-genetic regulation of brain tumor metastasis, with the goal of translating these discoveries into innovative therapies for malignant childhood brain tumors. He has held continuous NIH funding for over 10 years and has authored over 70 peer-reviewed publications in pediatric brain tumor research.
Melinda S. Merchant MD, PhD
Director of the Clinical Sarcoma Service, Branch of Pediatric Oncology of the National Cancer Institute
Dr. Merchant received her MD and PhD through the Physician Scientist Program at the University of Miami School of Medicine. Her graduate work was in the Department of Microbiology and Immunology and focused on B cell development. After completing residency training in Pediatrics at Children's National Medical Center in Washington, DC, she joined the Pediatric Oncology Branch as a clinical fellow in 1999. She received a NCI senior clinical fellowship award to remain at NCI for further postdoctoral training in the Immunology section under the mentorship of Dr. Crystal Mackall. In 2005, Dr. Merchant joined the faculty in the Department of Pediatrics at Memorial Sloan-Kettering Cancer Center and served as an Assistant Member and Attending Physician on the Pediatric Sarcoma Service. She returned to the Pediatric Oncology Branch in February 2009 and brings experience in the clinical management of childhood sarcomas as well as an active interest in the translation of immunotherapies and molcular targeted therapy in pediatric solid tumors, including bone and soft tissue tumors, melanoma, and neuroblastoma.
Rimas J. Orentas PhD
Associate Scientist, Branch of Pediatric Oncology, National Cancer Institute
Dr. Orentas received his B.S. in Microbiology from the University of Maryland, College Park. In 1991 he received his Ph.D. from the Department of Pharmacology and Molecular Sciences at The Johns Hopkins University School of Medicine, and also carried out post-doctoral Studies at the Hopkins Oncology Center, where he was promoted to a Research Associate. In 1996 he was recruited to the Medical College of Wisconsin in to the Department of Pediatrics, Section of Hematology-Oncology. At the Medical College of Wisconsin he rose to the rank of Associate Professor and was also appointed to the Department of Medicine and to the Department of Microbiology and Molecular Genetics where he participated in the graduate school training program. In 2008 Dr. Orentas was recruited to lead the Oncology program at Lentigen, Corp. in Gaithersburg, MD, where he was responsible for the scientific and clinical development of lentiviral gene vectors for both cancer and inherited disorders, focusing on T cell therapy, the engineering of marrow-derived stem cells and mesenchymal stem cells. From there he joined the Pediatric Oncology Branch of the NCI as a Staff Scientist in Dr. Crystal Mackall's laboratory in 2009 and was promoted to a National Cancer Institute Associate Scientist in 2012. Dr. Orentass current research centers on the engineering of T lymphocytes for the immunotherapy of cancer in both mouse and human systems. He has led preclinical development of a new chimeric antigen receptor targeting CD22 on acute lymphoblastic leukemia and has also created several other original chimeric receptors targeting solid tumor associated antigens. Dr. Orentas' has interests in the study of the T cell response to transplantation associated viral pathogens such as BKV and EBV, in using cell-based vaccines as a model for treating pediatric malignancies, and in pioneering new ways to engineer anti-tumor T cells.
Steven Piantadosi MD, PhD
Design & Analysis of Oncology Clinical Trials, Director of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
Dr. Piantadosi is the Director of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center in Los Angeles. Dr. Piantadosi's role is to lead the Medical Center's programs in cancer research, treatment and education, enhance academic activities related to cancer, and bring together cancer physicians and researchers for innovative collaborations. Prior to joining Cedars-Sinai in April 2007, Dr. Piantadosi was professor of oncology at The Johns Hopkins University School of Medicine and Director of Biostatistics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He also was professor of biostatistics and professor of epidemiology at the university's Bloomberg School of Public Health. After earning his medical degree from the University of North Carolina and doctorate in Biomathematics from the University of Alabama at Birmingham, Dr. Piantadosi became a senior staff fellow at the National Cancer Institute. Dr. Piantadosi is one of the world's leading experts in the design and analysis of clinical trials for cancer research. In addition to advising both FDA and industry, he has served on external advisory boards for the National Institutes of Health and other prominent cancer programs and centers. The author of more than 230 peer-reviewed scientific articles, Dr. Piantadosi currently serves as senior editor of the journal Clinical Cancer Research.
Stephen S. Roberts MD
Dr. Roberts is a pediatric oncologist at Memorial Sloan-Kettering Cancer Center in New York City.
Founding Scientific Advisory Board
SKC's Founding Scientific Advisory Board helped create our programming strategy and were instrumental in shaping the vision and guiding principles of the organization from our beginning.
Kenneth J. Cohen MD, MBA
Director Pediatric Neuro-oncology, Johns Hopkins University
Elizabeth A. Raetz MD
Professor of Pediatrics, Medical Director, High Risk Leukemia and Lymphoma Program, Huntsman Cancer Institute, University of Utah
Giselle Sholler MD
Associate Professor, Haworth Family Endowed Director of Innovative Therapeutics Clinic Pediatric Oncology, Helen DeVos Children's Hospital
With the concerted effort of SKC's staff, the organization aims to optimize resources and support the organizational mission. These key people handle day-to-day operations, fundraising efforts, and overall management so SKC can continue to strive towards finding solutions to deadly childhood cancers.
Scott Kennedy MBA
Co-founder and Executive Director
Scott co-founded SKC in 2007 as a tribute to his son, Hazen Kennedy, who was diagnosed with neuroblastoma at age 3. Hazen was Scott’s inspiration for creating Solving Kids' Cancer in part because Hazen wanted to become a scientist when he grew up in order to help people by creating new medicines. As Executive Director, Scott Kennedy is involved in all aspects of SKC, from managing operational staff and fundraising to policy development and fiscal management. He is integrally involved in the identification, funding, and management of the organization’s scientific programs. Before co-founding SKC, Scott worked in marketing at CDW in Chicago and Pfizer in New York City. He also founded a New York City theatre and sightseeing business, Manfreakinhattan. Scott has a Bachelor of Science in Chemistry and Psychology from Indiana University and a MBA from the Asian Institute of Management.
Eileen Kleiman MBA
Eileen joined SKC in 2013, bringing two years of nonprofit accounting and budgeting experience. Before taking a hiatus from work to raise her two children, Eileen had an extended career in the financial services industry where she co-founded and served as general partner of a risk-arbitrage investment fund. She has an MBA from the MIT Sloan School of Management and a Bachelor of Arts degree in applied mathematics from Harvard-Radcliffe College.
Donna Ludwinski BSChE
Co-Director, Research Programs & Partnerships
Admiration for the SKC mission and method noted while her son Erik battled neuroblastoma led to a productive collaboration after his death in 2010. Donna is a voracious consumer of medical literature and has has spent most of her waking hours the past 8 years reading and reporting on clinical and pre-clinical papers and abstracts on pediatric solid tumors. She attends major oncology conferences and keeps abreast of promising research leads. A lay member of the TDI, she assists in identifying, analyzing, and cultivating promising therapeutic leads to bring novel therapies into the clinic quickly. Passionate about providing resources and advocating for families dealing with childhood cancer, she also serves as a liaison with other foundations with similar goals and focus. Donna has a BS in Chemical Engineering, and recently relocated to West Virginia with her husband Paul and their two grown children Karl and Lesa (and their families). Paul and Donna have one son still at home, Aron.
After two years of both volunteer and freelance work for SKC, Kristi packed and moved from her home in Syracuse, NY to work full-time for the charity in 2012. She comes with 15 years of not-for-profit administrative experience along with a history of management, graphic design, fundraising, development, and event planning. She served on the board of directors for Redhouse Arts Center for seven years before relocating to NYC.
Director of Communications
Jenny has a decade of experience in health care communications, with expertise in medical writing and reporting for trade and consumer publications. She has a bachelor's degree in Magazine Journalism from Syracuse University. She is an award-winning journalist and was a 2009 Cancer Issues Fellow of the National Press Foundation. As the Director of Communications, she is responsible for developing and managing SKC's key messaging and strategic communications.
The Solving Kids' Cancer Leadership Council constitutes dedicated individuals who work in support of our mission. The work of the Council is in close collaboration with both the board and staff.
Suzan Mikiel Kennedy
Suzan Mikiel Kennedy tends to take a deep breath before she explains how she came to choose her line of work as Director of Development of Team Continuum, a charity that helps cancer patients and their families with their non-medical needs. The answer is not so casual. The answer is deep and passionate. Hazen Kennedy, her son, lost his sweet breath to neuroblastoma. Hazen is one of the most amazing people that would have grown up to make this world a better place. Suzan's involvement in the world of cancer is not by choice, but by necessity, and to honor Hazen's memory. She looks forward to working with SKC on fundraising events to help eradicate pediatric cancer so that the parents of thousands of other amazing children can choose a different line of work! As an actor, writer, avid iPhone photographer, Suzan has a variety of creative interests, and looks forward to applying her artistic experience towards the success of scientic endeavors.
Born and raised in Fresh Meadows, NY about 20 minutes outside of NYC, Lee obtained her Bachelors degree in Mass Communication from Towson University in 2004. Currently, she does residential Sales and Rentals for Prudential Douglas Elliman. She has always had a passion and been involved with children in one way or another throughout her life. Lee got involved with SKC after her beautiful cousin sadly lost her 3 year battle with neuroblastoma at the young age of 8. This is a cause close to her heart and she hopes to be involved on the fundraising end for many years to come.
Bethany is a survivor of childhood cancer and is thrilled to be able to help the fight to improve the odds for every kid. She and her husband are the proud owners an 1887 Victorian home, and blogs about her home improvement adventures at thelarsenslivehere.wordpress.com. Bethany also serves on the Advisory Board of the Fordham Alumni Theatre Company.
Katie Nitti is extremely excited to be a part of SKC. She in a resident and small business owner in Manhattan running a boutique dog walking company; Dog Walk NYC. She enjoys traveling, reading, sports and spending time in the city with her friends and family. Katie moved to Manhattan after graduating from The Catholic University in 2006 and spending six months volunteering in Ireland for CASA Breakhouses an organization offering respite care to people with disabilities.
Jordan Reed is a current resident of Manhattan and graduated from the University of Michigan in 2007. He currently works at Highline Capital Management as a trader. Jordan is an avid golfer and obsessed sports fanatic. He also enjoys reading and traveling. He joined SKC in early 2009 and was appointed the Junior Board Chairman shortly afterwards.
The Junior Board comprises a talented group of New York City based young professionals who serve as ambassadors of SKC in the community by articulating our mission, goals and unique therapeutic development model. They work together as an affiliate board of the SKC Board of Directors to create and produce events that help the organization meet its development goals.
Joelle is the Design and Communications Officer at WaterAid, an international non-profit that helps bring water and toilets to people in the poorest parts of the world. Prior to her involvement with SKC, she volunteered with the Peds Pals program, bringing cheer to children at Methodist Hospital. After fellow SKC member, Gina Scibelli introduced her to the organization and following her little cousin's battle and survival of pediatric cancer, she became increasingly interested in supporting the cause. She earned a degree in Communications Design from Pratt Institute and lives in Brooklyn. Joelle is excited to use her skills to help bolster awareness for Solving Kids' Cancer's mission.
Marina is a Drexel University graduate with a Health Sciences degree and is currently a Research Secretary at The Immigrant Health & Cancer Disparities Service of Memorial Sloan-Kettering Cancer Center. Her first exposure to nonprofits was during an internship with the Philadelphia Ronald McDonald House. When she moved back to NYC, she wanted to continue learning about health issues surrounding children. She was lucky enough to come across Solving Kids' Cancer, joining the Jr. Board in 2012, and has loved being a part of this incredible organization ever since. In addition to volunteering, Marina is an avid tweeter and enjoys participating in flash mobs.
Sharon Klein joined SKC in 2011 after her sister Lee introduced her to the organization. This cause became close to both their hearts after losing their beautiful 8 year old cousin, Shir, to Neuroblastoma in 2006. Sharon received her B.A. in Social Sciences from the University at Buffalo in 2008 and her Juris Doctor from Hofstra University School of Law (now the Maurice A. Deane School of Law at Hofstra University) in 2011. She is currently an Associate at Windels Marx Lane & Mittendorf, LLP, in New York City. Sharon plans to continue her involvement and contribution to reaching goals of the Junior Board and the organization as a whole for many years to come.
Rijul is a Community Outreach Administrative Assistant at The Immigrant Health & Cancer Disparities Service of Memorial Sloan Kettering Cancer Center. He is extremely passionate about serving as an advocate for the health needs of communities and individuals. Through previous volunteering with Teach for America, he provided a support system for children in an underserved community. He is really excited to continue being an advocate for children through Solving Kids' Cancer.
Emily is extremely excited to join SKC! As a pediatric cancer survivor herself, she is particularly excited to support Solving Kids' Cancer and its mission. Emily was diagnosed with Acute Lymphoblastic Leukemia when she was nine and she is now a proud survivor of 18 years! Emily earned her BA in Psychology from the University at Buffalo and currently works at LinkedIn.
Arielle is very excited to be a part of SKC. She currently works in Risk Management at American Express, and has recently finished her Master in Public Health (MPH) part-time at Columbia University. She completed her undergraduate degree at Washington University in St. Louis and currently lives in Manhattan. Arielle enjoys exploring the city and traveling to new places.
Whitney Scully has lived in Manhattan since 2005, employed as a Business Process and Technology Consultant. She came to New York from Baltimore, Maryland and received a degree in Logistics, Transportation, and Supply Chain Management from the University of Maryland.
Janel sits on the Junior Board of Solving Kids' Cancer and strives to help advance their mission of improving the survival rates of kids battling the deadliest childhood cancers. She is currently an Associate at Youth, I.N.C., a venture philanthropy organization that invests in small to mid-sized nonprofits through capacity building programs and cash grants. Previously, Janel worked in both programs and development at The Promise Foundation's flagship program, CAI, and A Bridge for Children International. Based in Beijing, China, the organizations were dedicated to serving orphans and children of migrant laborers-- two of the most vulnerable and at-risk populations in China. Janel received her undergraduate degree in Psychology, with a minor in Sociology, from Barnard, the Women's College of Columbia University.
Partners and Associate Organizations
Every day, SKC partners with great like-minded people and organizations in various ways that are aligned with our mission. We passionately believe that together we can provide real solutions to all children with these deadly childhood cancers where they are currently none. We look forward to a continued partnership and acknowledge that without their support and partnership we would not exist.
Andrew McDonough B+ Foundation
The Andrew McDonough B+ Foundation honors the life of 14-year-old Andrew who battled leukemia before leaving us on 7/14/2007. Andrew's B+ blood type became the perfect message "Be Positive." The B+ Foundation is about kids helping kids fight cancer -- by providing financial and emotional support to families of children with cancer, and by providing childhood cancer research grants.
The Catherine Elizabeth Blair Memorial Foundation
The mission of The Catherine Elizabeth Blair Memorial Foundation is to support funding for neuroblastoma research and treatment development.
The EVAN Foundation
Evan's Victory Against Neuroblastoma (EVAN) Foundation was established in memory of Evan Lindberg who bravely battled neuroblastoma for four years before passing away at the age of 7 in 2010. The Foundation funds research aimed at fostering new treatment options for children with neuroblastoma, and sponsors patient-wellness programs for childhood cancer patients enduring long and difficult stays in the hospital. The Foundation is a 501(c)(3) nonprofit charity.
Fitzgerald Cancer Fund
The mission of the Fitzgerald Cancer Fund is to battle neuroblastoma better by finding and funding less toxic treatments for neuroblastoma that focus on high quality of life for patients and by financially assisting families who have a child in treatment for NB.
Joining Against Cancer in Kids was established in 2008, â€“ in addition to bringing therapies to the UK, a further aim was to improve existing treatment protocols for children with neuroblastoma as well as research into new treatments for this devastating cancer. The initiative was supported by officers of the Metropolitan Police Service, and also by family and friends of Jack Brown. Since the establishment in 2008, the support for J-A-C-K has become truly UK wide, including some very high profile supporters, and successful fundrasing events have taken place from the South of England to the North of Scotland.
The James Fund
Fund for neuroblastoma research established at SickKids Foundation where all funding goes directly to research and investigation efforts for neuroblastoma therapies
A group of parents striving to find solutions for their children with neuroblastoma and medulloblastoma
The Make Some Noise: Cure Kids Cancer Foundation
The Make Some Noise: Cure Kids Cancer Foundation was established by a child with cancer with one purpose in mind: to fund pediatric cancer research.
The NCCA UK helps children access potentially life-saving treatment, whilst supporting research that not only aims to introduce new treatments but also bring existing internationally available options here to the UK. We support parents by sharing the most current resources available for neuroblastoma treatments and providing access to other parents who want to share their knowledge and experiences. - See more at: http://www.ncca-uk.org/ncca-uk#sthash.sXmTC7yp.dpuf
Pierce Phillips Charity
Pierce Phillips (7/30/2007-10/9/2009) is the inspiration for Scott and Brandi Phillips, and the Pierce Phillips Charity. PPC exists to make progress in the fight against Neuroblastoma and other forms of childhood cancers by directing funds to research and trials that can increase survivorship now and that will eventually lead to a cure for the most innocent of cancer victims.
The Ronan Thompson Foundation
The mission of The Ronan Thompson Foundation is to cure children with neuroblastoma. The Foundation raises funds for research that will find new and innovative ways to treat neuroblastoma, and ultimately, find a cure for this disease.
The Ty Louis Campbell Foundation
The Ty Louis Campbell Foundation is a nonprofit organization, certified 501(c)(3), that funds innovative research and clinical trials specifically geared toward the treatment of the deadliest childhood cancers (including brain and spinal cord tumors). Our organization seeks less toxic, more effective treatments that are specifically designed for children fighting cancer. Our ultimate mission is to help fund the intelligence and technology that will uncover new ways to cure children with cancer
The mission of Wade's Army is to fund research and bring support to the brave children and families affected by this often fatal pediatric cancer.